Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers

PHASE3CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

December 26, 2018

Primary Completion Date

August 19, 2021

Study Completion Date

December 6, 2021

Conditions
Diabetic Foot Ulcer
Interventions
DRUG

Esmolol Hydrochloride

Galnobax-14% gel application along with Standard of Care

OTHER

Only Standard of Care

Only Standard of Care treatment

OTHER

Vehicle Gel

Vehicle gel application along with Standard of Care

Trial Locations (14)

110012

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

110026

Maharaja Agrasen Hospital, New Delhi

411004

Deenanath Mangeshkar Hospital and Research Center, Pune

411021

Chellaram Diabetes Institute, Pune

422101

Sujata Birla Hospital & Medical Research Center, Nashik

520002

Yalamanchi Hospita, Vijayawada

560054

M.S. Ramaiah Medical College and Hospital, Bangalore

560090

Sapthagiri Institute of Medical Sciences and Research Centre, Bangalore

560097

Rajlaxmi Hospital, Bangalore

572107

Sri Siddhartha Medical College, Tumkūr

600006

Appollo Hospital, Chennai

600013

M.V. Hospital for Diabetes Pvt Ltd, Chennai

600086

Madras Diabetes Research Foundation, Chennai

600116

Sri Ramachandra Hospital, Chennai

All Listed Sponsors
lead

Novalead Pharma Private Limited

INDUSTRY

NCT03998436 - Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter